| Influenza
Rapivab vs Xofluza
Side-by-side clinical, coverage, and cost comparison for influenza.Deep comparison between: Rapivab vs Xofluza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXofluza has a higher rate of injection site reactions vs Rapivab based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xofluza but not Rapivab, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rapivab
Xofluza
At A Glance
IV infusion
Single dose
Neuraminidase inhibitor
Oral
Single dose
PA endonuclease inhibitor
Indications
- Influenza
- Influenza
Dosing
Influenza (adults and adolescents >=13 years) Single 600 mg IV dose over 15-30 minutes within 2 days of symptom onset; reduce to 200 mg for CrCl 30-49 mL/min or 100 mg for CrCl 10-29 mL/min; administer after dialysis in hemodialysis patients.
Influenza (pediatric patients 6 months to 12 years) Single 12 mg/kg dose (up to 600 mg) IV over 15-30 minutes within 2 days of symptom onset; proportional dose reduction for CrCl 30-49 or 10-29 mL/min in patients >=2 years; no dose adjustment recommendation available for patients <2 years with CrCl <50 mL/min.
Influenza Single weight-based oral dose for treatment (within 48 hours of symptom onset) and post-exposure prophylaxis in patients 5 years of age and older: 40 mg for 20 to <80 kg, 80 mg for >=80 kg; pediatric patients <20 kg receive 2 mg/kg.
Contraindications
- Known serious hypersensitivity or anaphylaxis to peramivir or any component of the product
- History of hypersensitivity to baloxavir marboxil or any of its ingredients (serious reactions have included anaphylaxis, angioedema, urticaria, and erythema multiforme)
Adverse Reactions
Most common (>=2%) Diarrhea, elevated serum glucose, neutropenia, elevated creatine phosphokinase, elevated ALT; vomiting reported in pediatric patients
Serious Serious skin and hypersensitivity reactions (including erythema multiforme, Stevens-Johnson syndrome), neuropsychiatric events
Postmarketing Stevens-Johnson syndrome, exfoliative dermatitis, rash, anaphylactic/anaphylactoid reactions, abnormal behavior, hallucination
Most common (>=1%) Diarrhea, bronchitis, nausea, sinusitis, headache (in adults and adolescents >=12 years)
Postmarketing Anaphylactic reactions, anaphylactic shock, anaphylactoid reactions, hypersensitivity reactions, angioedema, rash, urticaria, erythema multiforme, vomiting, hematochezia, melena, colitis, delirium, abnormal behavior, hallucinations
Pharmacology
Peramivir is an inhibitor of influenza virus neuraminidase, an enzyme that releases viral particles from the plasma membrane of infected cells, thereby inhibiting the spread of virus from infected cells. It is not significantly metabolized and is primarily eliminated renally, with no meaningful CYP-mediated drug interactions expected.
Baloxavir marboxil is a prodrug converted to baloxavir, which inhibits the endonuclease activity of the influenza virus polymerase acidic (PA) protein, blocking viral gene transcription and inhibiting influenza A and B virus replication.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rapivab
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Xofluza
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Rapivab
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xofluza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Rapivab
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Xofluza
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rapivab.
No savings programs available for Xofluza.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RapivabView full Rapivab profile
XofluzaView full Xofluza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.